Skip to main content
SpringerLink
Log in

Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice

  • Original Paper
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Abstract

Sertraline potently inhibits cytochrome P450 2B6 (CYP2B6) in vitro. Bupropion is commonly co-prescribed with sertraline and is exclusively metabolized by CYP2B6 to its major active metabolite hydroxybupropion. Putatively the co-administration of bupropion and sertraline could lead to a significant pharmacokinetic drug–drug interaction. The aim of this study was to evaluate a possible drug interaction between these drugs in mice. To study this male CF-1 mice were administered sertraline 5 mg/kg once daily for 6 days, followed by a single dose of bupropion 50 mg/kg on the seventh study day. Plasma and brain samples were collected post-bupropion dose for measurement of bupropion and hydroxybupropion levels on HPLC. Pharmacokinetic parameters for bupropion and hydroxybupropion were calculated using noncompartmental analysis and the variance in AUC of each was computed using Bailer’s analysis. We found that mice pretreated with sertraline exhibited a small elevation in bupropion metabolism. This was substantiated by Bailer’s analysis which indicated that in the presence of sertraline, both plasma and brain bupropion exposure were significantly (p < 0.05) decreased, while plasma hydroxybupropion exposure was significantly (p < 0.05) increased. Also the plasma hydroxybupropion-to-bupropion ratio of AUC was increased by 27% in sertraline treated mice, indicative of increased CYP2B activity. This is the first study, to our knowledge, that reports a mild pharmacokinetic drug–drug interaction between bupropion and sertraline in mice. However, it is unknown whether these quantitative changes in enzyme activity and consequent drug exposure would equate to significant pharmacodynamic changes (e.g., perturbations in brain neurotransmitter levels) observed in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16(3):303–309

    Article  PubMed  CAS  Google Scholar 

  • Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M et al (2008) Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Saf 31(11):1017–1026

    Article  PubMed  CAS  Google Scholar 

  • Daniel WA, Haduch A, Syrek M, Boksa J (2006) Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. Eur Neuropsychopharmacol 16(8):580–587

    Article  PubMed  CAS  Google Scholar 

  • Davies TS, Kluwe WM (1998) Preclinical toxicological evaluation of sertraline hydrochloride. Drug Chem Toxicol 21(4):521–537

    Article  PubMed  CAS  Google Scholar 

  • DeBattista C (2006) Augmentation and combination strategies for depression. J Psychopharmacol 20(3 Suppl):11–18

    Article  PubMed  CAS  Google Scholar 

  • DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF (2003) A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol 23(1):27–30

    Article  PubMed  CAS  Google Scholar 

  • Desager JP (1994) Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 26(5):347–355

    Article  PubMed  CAS  Google Scholar 

  • DeVane CL, Liston HL, Markowitz JS (2002) Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 41(15):1247–1266

    Article  PubMed  CAS  Google Scholar 

  • Ekins S, Wrighton SA (1999) The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31(3):719–754

    Article  PubMed  CAS  Google Scholar 

  • Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, Li Q, Zhang W, Wang G, Lei HP, Hu DL, Wang D, Zhou HH (2009) Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol 65(4):403–409

    Article  PubMed  CAS  Google Scholar 

  • Haduch A, Wojcikowski J, Daniel WA (2005) Effect of short- and long-term treatment with antidepressant drugs on the activity of rat CYP2A in the liver. Pharmacol Rep 57(6):774–781

    PubMed  CAS  Google Scholar 

  • Haduch A, Wojcikowski J, Daniel WA (2008) Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep 60(6):957–965

    PubMed  CAS  Google Scholar 

  • Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28(10):1176–1183

    PubMed  CAS  Google Scholar 

  • Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, Yamada S (2005) Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144(5):695–702

    Article  PubMed  CAS  Google Scholar 

  • Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM (2007) Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 81(1):69–75

    Article  PubMed  CAS  Google Scholar 

  • Kharasch ED, Mitchell D, Coles R, Blanco R (2008) Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 52(5):1663–1669

    Article  PubMed  CAS  Google Scholar 

  • Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K (1999) Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 27(7):763–766

    PubMed  CAS  Google Scholar 

  • Kreilgaard M, Smith DG, Brennum LT, Sanchez C (2008) Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice. Br J Pharmacol 155(2):276–284

    Article  PubMed  CAS  Google Scholar 

  • Laizure SC, DeVane CL, Stewart JT, Dommisse CS, Lai AA (1985) Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 38(5):586–589

    Article  PubMed  CAS  Google Scholar 

  • Lau AJ, Chang TK (2009) Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols. Drug Metab Dispos 37(9):1931–1937

    Article  PubMed  CAS  Google Scholar 

  • Molnari JC, Hassan HE, Moeller BM, Myers AL (2011) Drug interaction study between bupropion and ticlopidine in male CF-1 mice. Biol Pharm Bull 34(3):447–451

    Article  PubMed  CAS  Google Scholar 

  • Obach RS, Cox LM, Tremaine LM (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33(2):262–270

    Article  PubMed  CAS  Google Scholar 

  • Rudkin L, Taylor MJ, Hawton K (2004) Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev (4):CD003382

  • Shepherd G (2005) Adverse effects associated with extra doses of bupropion. Pharmacotherapy 25(10):1378–1382

    Article  PubMed  CAS  Google Scholar 

  • Suckow RF, Smith TM, Perumal AS, Cooper TB (1986) Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Drug Metab Dispos 14(6):692–697

    PubMed  CAS  Google Scholar 

  • Talakad JC, Kumar S, Halpert JR (2009) Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos 37(3):644–650

    Article  PubMed  CAS  Google Scholar 

  • Taylor MJ, Rudkin L, Hawton K (2005) Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord 88(3):241–254

    Article  PubMed  CAS  Google Scholar 

  • Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K (2005) Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77(6):553–559

    Article  PubMed  CAS  Google Scholar 

  • Walsky RL, Obach RS (2007) A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1′,1″-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab Dispos 35(11):2053–2059

    Article  PubMed  CAS  Google Scholar 

  • Walsky RL, Astuccio AV, Obach RS (2006) Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 46(12):1426–1438

    Article  PubMed  CAS  Google Scholar 

  • Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ (2006) Population pharmacokinetic analysis of drug–drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl) 183(4):490–499

    Article  CAS  Google Scholar 

  • Welch RM, Lai AA, Schroeder DH (1987) Pharmacological significance of the species differences in bupropion metabolism. Xenobiotica 17(3):287–298

    Article  PubMed  CAS  Google Scholar 

  • Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB (2006) Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 59(3):203–210

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was graciously supported in part by the Drake University College of Pharmacy and Health Sciences and Drake University Office of the Provost for which the authors gratefully acknowledge.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical, Biomedical and Administrative Sciences, College of Pharmacy and Health Sciences, Drake University, 2507 University Avenue, Des Moines, IA, 50266, USA

    Jillissa C. Molnari & Alan L. Myers

  2. Pharmacokinetics and Biopharmaceutics Laboratory, School of Pharmacy, University of Maryland, 20 North Pine Street, Baltimore, MD, 21201, USA

    Hazem E. Hassan

  3. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Helwan University, Helwan, Egypt

    Hazem E. Hassan

Authors
  1. Jillissa C. Molnari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hazem E. Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alan L. Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan L. Myers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molnari, J.C., Hassan, H.E. & Myers, A.L. Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice. Eur J Drug Metab Pharmacokinet 37, 57–63 (2012). https://doi.org/10.1007/s13318-011-0065-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-011-0065-6

Keywords

Search

Navigation